R&D Supporting Pilot Study for the Assessment of the Safety and Effectiveness of the ProVATE (ProTIPI) Vaginal Pessary
NCT ID: NCT02239133
Last Updated: 2015-12-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
44 participants
INTERVENTIONAL
2014-08-31
2016-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Subject screening will be held during visit one (1) and visit two (2) at the clinic.
Initiation and Size fitting:
All eligible subjects will undergo size fitting by a gynecologist / urogynecologist, during visit 2, to find the suitable size for her. The subject will use the ProVATE device of the chosen size at the clinic vicinity for about one (1) hour and for 40-80 hours at her home environment, to confirm that the chosen size is appropriate for the user. Each usage will be followed by a vaginal examination. In case the investigator will determine that the subject should be fitted with a different size of the ProVATE device the subject will repeat this stage with a different device size until the suitable size is confirmed by the investigator.
Usage:
The subject will use the ProVATE device for at least 28 days during a 45 days period, at her home environment, and fill a usage diary. Each device will be used for at least 24 hours. At least one (1) follow-up phone call will be held with the subject per a week. After 14 usage days or following at least two (2) usages (the latest of them) the subject will be scheduled for vaginal examination at the clinic (visit four (4)).
End Of Use At the end of use the subject will return to the clinic (visit five (5)) for a vaginal examination and additional activities.
The following questionnaires will be filled at baseline and end of study: Quality Of Life (QoL) and POP symptoms. Satisfaction and Ease Of Use questionnaires will be filled at the end of use (visit 5) Up to four (4) ProVATE device models will be tested in this study.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ProVATE vaginal pessary
The ProVATE device is a disposable, single-use, vaginal pessary for the management of Pelvic Organ Prolapse ("POP"). The ProVATE device is similar to other ring pessaries currently on the market. Its features allow for easy and comfortable insertion and removal by the user herself at her home environment. The ProVATE device is provided in six (6) different sizes and is intended for prescription use only.
ProVATE vaginal pessary
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ProVATE vaginal pessary
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Ability to use both hands and insert a device into the vagina
* Ability to attend the study site as explained by the investigator
* A symptomatic sensation of vaginal prolapse
* The subject has the ability to understand the nature of the study and sign the informed consent
* On examination, the presence of a vaginal wall prolapse of one or more sites
* On examination, POP-Q grade 2 - 4 POP is demonstrated
* A 61-91 mm pessary is well fitted
* A 61-91 mm pessary is well retained
Exclusion Criteria
* Subject is currently participating in another clinical study which may directly or indirectly affect the results of this study
* Co-morbid condition(s) or severe systemic disease that could limit the subject 's ability to participate in the study, or impact the scientific integrity of the study
* Subject is pregnant, or suspected to be pregnant or is planning to be pregnant during the course of the study
* Abnormal vaginal bleeding in the past 6 months
* Previous vaginal surgery during the last 3 months
* A severely atrophic vagina
* Existing vaginal or vulvar laceration
* Symptomatic vaginal infection as determined by physical examination and lab results
* Symptomatic urinary tract infection as determined by physical examination and lab results
* Recurrent urinary tract infections
* Abnormal cervical cytology
21 Years
80 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ConTIPI Medical
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Site 01
Herzliya, , Israel
Site 02
Herzliya, , Israel
Site 03
Ramat HaSharon, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ProVATE PT 103
Identifier Type: -
Identifier Source: org_study_id